. A variety of imaging modalities, including positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), optical imaging, and high frequency 3D-ultrasound are now available, each with unique advantages and limitations 11 . Bioluminescence imaging (BLI) studies, for example, have the advantage of being relatively low cost and high-throughput. It is for this reason that, in this study, we make use of the firefly luciferase (fluc) reporter gene sequence contained within the fusion gene and bioluminescence imaging (BLI) for the short-term localization of viable C2C12 myoblasts following implantation into a mouse model of DMD (muscular dystrophy on the X chromosome [mdx] mouse) [12] [13] [14] . Importantly, BLI provides us with a means to examine the kinetics of labeled MPCs post-implantation, and will be useful to track cells repeatedly over time and following migration. Our reporter gene approach further allows us to merge multiple imaging modalities in a single living subject; given the tomographic nature, fine spatial resolution and ability to scale up to larger animals and humans 10, 11 , PET will form the basis of future work that we suggest may facilitate rapid translation of methods developed in cells to preclinical models and to clinical applications.
Video Link
The video component of this article can be found at http://www.jove.com/video/50119/ Protocol 1. Maintenance and Propagation of C2C12 Myoblasts Balanced Salt Solution (HBSS) to remove all traces of culture medium, which contains trypsin-inhibiting serum. Briefly rinse the cell layer with 2-3 ml 0.25% (w/v) trypsin-EDTA solution to dissociate the adherent myoblasts from the flask. Aspirate trypsin and place flask in incubator at 37 °C for 5 min. 3. During this incubation, prepare a new flask with 9 ml of HG-DMEM/10% FBS medium. After trypsinization, add 10 ml of complete medium to cells and pipette 4-5 times to ensure collection of all cells in the medium. Add 1 ml of cell suspension to the new flask and incubate in 5% CO 2 at 37 °C.
Representative Results
Upon 50-60% confluency, C2C12 myoblasts were transiently transfected with the above-mentioned fusion reporter gene construct composed of firefly luciferase [fluc], monomeric red fluorescent protein [mrfp] and sr39 thymidine kinase [sr39tk]( Figure 1A) . Transfection efficiency was calculated via fluorescence microscopy ( Figures 1B,C) , making use of the mrfp sequence in our reporter construct. Cell survivability was not affected by labeling with the BLI substrate, D-luciferin ( Figure 1D ). Following transfection, approximately 100,000 mrfp-expressing myoblasts were implanted intramuscularly into the gastrocnemius muscle of mdx mice (determined previously, manuscript submitted); 100,000 untransfected cells were similarly implanted into the contralateral hind limb as a control. Immediately following cell implantation, mice were injected intraperitoneally (IP) with 150 mg/kg D-luciferin. Following an uptake period of ~20 min, mice were imaged on a small animal optical scanner (GE ExplorOptix black box that is equipped for live animal bioluminescence and fluorescence). As previously demonstrated, both in vitro and post-implantation (manuscript submitted) uptake of D-luciferin was specific to fluc-expressing myoblasts, with no detectable bioluminescence in untransfected cells (Figure 2) . Immunohistochemistry confirmed intramuscular transplantation of myoblasts (Figure 3 
Discussion
In this study, we have described a fast and reliable molecular imaging, reporter gene approach to non-invasively target myoblasts/MPCs following transplantation. While this study demonstrates the short-term localization of transplanted MPCs via bioluminescense imaging (BLI), the manner in which cells are targeted can, in fact, be easily applied to a longitudinal assessment of cell engraftment, through the implantation of cells that stably express the reporter gene. To this end, our group has generated transgenic mouse lines that harbor the unified reporter gene. Only cells expressing the reporter gene oxidize D-luciferin to produce photons for visualization using BLI. Since oxidation of D-luciferin is dependent on gene expression, this is a powerful technology with which to non-invasively image viable transplanted cells. Muscle tissue harvested from these transgenic mice and satellite cells (SCs) isolated via FACS can indeed be targeted following implantation into mdx mice. Additionally, we can track their differentiation status through the use of a muscle-specific promoter, further heightening the usefulness and importance of molecular imaging technologies, such as presented herein, to the field of DMD research (manuscript submitted). In addition to its rapidity and low-cost, BLI is non-toxic, making it an attractive choice for frequent imaging of small animals. This feature, as well as its high specificity, will be invaluable in refining myoblast replacement therapies in pre-clinical disease models of Duchenne muscular dystrophy before advancing to clinically-applicable studies involving technologies such as PET.
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